Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

AndroGel Adult (30-49) Dosing: Complete Clinical Guide

By
Published Updated Last reviewed
4 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Label covered / generic testosterone gel 1% (Teva), not AndroGel 1.62% [1]
  • Starting dose, gel 1% / 50 mg once daily in the morning [1]
  • Dose steps / 50, 75 or 100 mg, set by serum testosterone [1]
  • Application sites / shoulders, upper arms and/or abdomen [1]
  • Hematocrit check / before starting, 3 to 6 months later, then yearly [1]
  • Controlled substance / Schedule III [1]

What the Gel 1% Label Says

The label is for replacement therapy in men with primary or hypogonadotropic hypogonadism, and says to confirm the diagnosis before starting with morning serum testosterone on at least two separate days, both below the normal range [1]. The starting dose is 50 mg once daily in the morning — 4 pump actuations, two 25 mg packets, or one 50 mg packet — on clean, dry, intact skin of the shoulders and upper arms and/or abdomen, and not on the genitals, chest, armpits, knees or back [1]. For adjustment, the label says serum testosterone should be measured at intervals: if it is below the normal range, the dose may be increased from 50 to 75 mg and from 75 to 100 mg; if it exceeds the normal range, the dose may be decreased; and if it consistently exceeds the normal range at 50 mg a day, the label says therapy should be discontinued [1].

Why the 1% label cannot give an AndroGel 1.62% dose

The gel 1% label says topical testosterone products may have different doses, strengths or application instructions that may result in different systemic exposure, and that the application site and dose of testosterone gel 1% are not substitutable with other topical testosterone products [1]. AndroGel 1.62% has its own prescribing information, so its starting dose, titration steps and maximum daily dose cannot be taken from the 1% label.

What the Label Says to Monitor

The label says serum testosterone should be measured at intervals and then assessed periodically, and that PSA, hemoglobin, hematocrit, liver function tests and lipids should be monitored periodically [1]. For hematocrit it says to check before starting, to re-evaluate 3 to 6 months after starting and then annually, and to stop therapy until hematocrit decreases to an acceptable level if it becomes elevated [1]. In a 4-month ambulatory blood pressure study of the 1% gel, the label reports a mean rise of 1.9 mm Hg in systolic and 1.3 mm Hg in diastolic pressure from baseline after 16 weeks [1]. The label says the gel is not recommended in men with uncontrolled hypertension [1].

Age-Related Hypogonadism: Where the Label Stands

In June 2026, FDA requested removal of the limitation of use for age-related hypogonadism and revision of prostate cancer and BPH safety information [4]. The testosterone gel 1% label (effective September 2025) still contains that limitation [1].

Frequently asked questions

What is the labeled starting dose for testosterone gel 1%?
50 mg once daily in the morning, as 4 pump actuations, two 25 mg packets, or one 50 mg packet, later adjusted to 50, 75 or 100 mg by serum testosterone [1]. The label itself says dosing differs from the 1.62% gel [1].
How often is hematocrit checked on the gel?
The label says to check before starting, re-evaluate 3 to 6 months after starting, then annually. If hematocrit becomes elevated, it says to stop therapy until hematocrit decreases to an acceptable concentration [1].
Does the testosterone gel label carry a boxed warning?
Yes, for secondary exposure. The boxed warning says virilization has been reported in children secondarily exposed to testosterone gel, and that children should avoid contact with unwashed or unclothed application sites [1].

References

  1. U.S. National Library of Medicine, DailyMed. Testosterone gel 1% topical (generic, Actavis Pharma for Teva) prescribing information. Testosterone gel 1% topical (generic, Actavis Pharma for Teva) label
  2. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline
  3. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. Evaluation and Management of Testosterone Deficiency: AUA Guideline
  4. Testosterone Information | FDA. Testosterone Information | FDA
Evidence overview for AndroGel Adult (30-49) Dosing: Complete Clinical Guide